Mechanism of bone metastasis: The role of osteoprotegerin and of the host-tissue microenvironment-related survival factors

被引：69

作者：

Fili, Sofia ^{[1
]}

Karalaki, Maria

Schaller, Bernhard

机构：

[1] Natl & Kapodistrian Univ Athens, Sch Med, Goudi 11527, Greece

来源：

CANCER LETTERS | 2009年 / 283卷 / 01期

关键词：

Bone microenvironment; Osteoblastic and osteolytic bone metastasis; Bone resorption; Osteoprotegerin; Receptor activator of nuclear factor-kappa B ligand; KAPPA-B LIGAND; BREAST-CANCER CELLS; HUMAN PROSTATE-CANCER; RANK LIGAND; RECEPTOR ACTIVATOR; IMPROVES SURVIVAL; MULTIPLE-MYELOMA; TUMOR BURDEN; EXPRESSION; OPG;

D O I：

10.1016/j.canlet.2009.01.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Osteoprotegerin (OPG), member of tumor necrosis factor (TNF) receptor superfamily, has various biological functions including bone remodeling. OPG binds to receptor activator of nuclear factor-kB ligand (RANKL) and prevents osteoclastic bone resorption. Recently, OPG has gained more clinical interest as its role in cancer-mediated bone destruction and the potential of RANKL inhibition could act as a novel treatment in tumor-induced bone disease. OPG protects prostate cancer cells from apoptotic effects of TRAIL and therefore provides tumor cells producing OPG with survival advantages. Additionally, the increased RANKL/OPG ratio in metastatic breast cancer results in severe osteolysis. Thus, bone formation and resorption are the crux of cancer metastasis, resulting in bone pain and pathological fractures. This review provides an overview of the role of OPC in cancer-induced bone disease. (C) 2009 Elsevier Ireland Ltd. All rights reserved.

引用

页码：10 / 19

页数：10

共 68 条

[1]

Abrahamsen B, 2005, CURR OPIN MOL THER, V7, P604

[2]

[Anonymous], ARCH MED SCI

[3]

Endothelin receptors as novel targets in tumor therapy [J].

Bagnato A. ;

Natali P.G. .

Journal of Translational Medicine, 2 (1)

[4]

Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-κB ligand pathway [J].

Bendre, MS ;

Margulies, AG ;

Walser, B ;

Akel, NS ;

Bhattacharrya, S ;

Skinner, RA ;

Swain, F ;

Ramani, V ;

Mohammad, KS ;

Wessner, LL ;

Martinez, A ;

Guise, TA ;

Chirgwin, JM ;

Gaddy, D ;

Suva, LJ .

CANCER RESEARCH, 2005, 65 (23) :11001-11009

[5]

BOCKER W, 2007, PATHOLOGY, P1577

[6]

A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer [J].

Body, JJ ;

Facon, T ;

Coleman, RE ;

Lipton, A ;

Geurs, F ;

Fan, M ;

Holloway, D ;

Peterson, MC ;

Bekker, P .

CLINICAL CANCER RESEARCH, 2006, 12 (04) :1221-1228

[7]

A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases [J].

Body, JJ ;

Greipp, P ;

Coleman, RE ;

Facon, T ;

Geurs, F ;

Fermand, JP ;

Harousseau, JL ;

Lipton, A ;

Mariette, X ;

Williams, CD ;

Nakanishi, A ;

Holloway, D ;

Martin, SW ;

Dunstan, CR ;

Bekker, PJ .

CANCER, 2003, 97 (03) :887-892

[8]

BORON WF, 2006, MED PHYSL CELLULAR M, P1413

[9]

Osteoprotegerin and rank ligand expression in prostate cancer [J].

Brown, JM ;

Corey, E ;

Lee, ZD ;

True, LD ;

Yun, TJ ;

Tondravi, M ;

Vessella, RL .

UROLOGY, 2001, 57 (04) :611-616

[10]

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification [J].

Bucay, N ;

Sarosi, I ;

Dunstan, CR ;

Morony, S ;

Tarpley, J ;

Capparelli, C ;

Scully, S ;

Tan, HL ;

Xu, WL ;

Lacey, DL ;

Boyle, WJ ;

Simonet, WS .

GENES & DEVELOPMENT, 1998, 12 (09) :1260-1268

← 1 2 3 4 5 6 7 →